Weight loss and changes in use of antidiabetic medication in XXXX diabetics after laparoscopic gastric banding.

@entity1 @entity353 @entity6 @entity28 @entity164
BACKGROUND: Interest in bariatric surgery is growing as an effective method for long-term metabolic control in morbidly @entity28 @entity1 with @entity164 2 @entity6 . We analyzed the @entity353 and changes in use of @entity6 medication in @entity28 @entity1 with @entity164 2 @entity6 treated with laparoscopic adjustable gastric banding (LAGB). METHODS: From 1993 to 2005, 1791 morbid @entity28 @entity1 underwent LAGB at our institution. Of the 1791 @entity1 , 394 (22%) had @entity6 at baseline. Of the 394 @entity1 with @entity6 , 52 were receiving @entity6 medication. The median follow-up period for the drug-treated @entity6 @entity1 was 3 years (range .25-9). RESULTS: The drug-treated @entity6 @entity1 were older (age 47.6 +/- 7.5 versus 37.5 +/- 10.7 years, P <.001), weighed more (body mass index 49.1 +/- 9.5 versus 45.6 +/- 7.5 kg/m(2), P 0.001), and were more frequently affected by co-morbidities than the nondiabetic @entity1 at surgery. The percentage of excess @entity353 1 year after surgery was less (32.4% +/- 14.1% versus 41.1% +/- 19.9%, P <.01) for the drug-treated @entity6 @entity1 than for the nondiabetic @entity1 . This difference was maintained for 5 years of follow-up. A significant decline occurred in the use of both oral @entity6 medication and insulin after surgery. Of the 52 @entity1 treated with oral antidiabetic medication at baseline, 33 required oral antidiabetic medication at the end of follow-up. Of the 6 @entity1 who also required insulin at baseline, 2 did so at the end of follow-up. The use of @entity6 medication had increased in 4 @entity1 (7.7%), was unchanged in 12 (23.1%), had decreased in 17 (32.7%), and was suspended in 19 (36.5%) of 52 @entity1 . CONCLUSION: The amount of @entity353 after LAGB was less in drug-treated @entity6 @entity1 than in nondiabetic @entity1 . However, LAGB was associated with a sustained reduction in the use of @entity6 medication.
